Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

Report the study before interpreting it

Each EternaGen evidence record names the study design, participant population, measured endpoints and a direct literature link. Human trials, translational studies and mechanistic experiments are labelled separately because they support different kinds of conclusions.

The registry includes published work involving Tesamorelin, Retatrutide, CJC-1295, Ipamorelin, thymosin beta 4, MOTS-c, GHK-Cu, NAD+, KPV and BPC 157. Inclusion means that a source was indexed for educational context; it is not an endorsement of a compound or commercial product.

Evidence should become more specific as a claim becomes more consequential.

What the indexed studies actually contain

The Tesamorelin record describes a randomized 12-month study of 404 adults living with HIV and excess abdominal fat. Retatrutide records now include phase 2 and 2026 phase 3 reporting. The MOTS-c records distinguish endogenous human sampling from administered-compound evidence.

The registry also preserves narrow or negative results: the Ipamorelin postoperative trial did not show significant differences on key efficacy analyses, the GHK-Cu human evidence is topical and formulation-specific, and the NAD+ infusion pilot was not an efficacy trial.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

Study findings stay separate from the product record

A literature record applies to the intervention, dose, protocol and population studied by the investigators. It does not authenticate a separately sold material and cannot be used to infer safety, efficacy or appropriate use outside the trial.

EternaGen does not use the registry to provide treatment guidance, personal recommendations or claims about human consumption.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 20 July 2026.

  1. Falutz et al. Tesamorelin randomized trial. J Acquir Immune Defic Syndr. 2010. PMID 20101189.
  2. Jastreboff et al. Retatrutide phase 2 trial. N Engl J Med. 2023. PMID 37366315.
  3. Reynolds et al. MOTS-c translational study. Nat Commun. 2021. PMID 33473109.
  4. Beck et al. Ipamorelin postoperative proof-of-concept trial. Dis Colon Rectum. 2014. PMID 25331030.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.